Show simple item record

dc.contributor.authorTayoun, Ahmad N. Abou
dc.date.accessioned2023-03-30T07:07:52Z
dc.date.available2023-03-30T07:07:52Z
dc.date.issued2022
dc.identifier.other204-2022.86
dc.identifier.urihttps://repository.mbru.ac.ae/handle/1/1100
dc.description.abstractIntroduction: Zhu et al assessed the utility of combining expanded genomic sequencing with traditional physiological newborn hearing screening (NBHS) in the neonatal intensive care unit (NICU). The benefits associated with combining genetic and physiological screening, as illustrated by Zhu et al1 and elsewhere,2 include the identification of babies at risk for hearing loss who can benefit from early intervention yet are missed by NBHS, as well as genetic factors that may help improve the management of hearing loss in confirmed cases. In a cohort of 8078 patients admitted to the NICU, Zhu et al1 show that exome sequencing identified 7 patients with hearing loss who already had a negative NBHS test result (false negatives), thus increasing the total number of patients with confirmed hearing loss by 13.5% (7 of 52) in this setting. Furthermore, of all patients with confirmed hearing loss, 75.0% (39 of 52) had genetic findings, thus also providing important genetic information for a substantial proportion of patients.en_US
dc.language.isoenen_US
dc.subjectGenomic Sequencingen_US
dc.subjectHearing Lossen_US
dc.subjectNeonatal Intensive Careen_US
dc.titleComprehensive Genomic Sequencing–Based Screening for Hearing Loss in the Neonatal Intensive Care Setting—Is It Time?en_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record